By targeting HIF-1α and other factors that either promote tumour hypoxia or contribute to the hypoxia cycle, the tumour itself may be halted in a state of oxygenation, thereby increasing the number of ROS during radiation and subsequent DNA damage. The gene discussed is HIF1A; the disease is neoplasm.